With 0.55 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.74 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $51.25 whereas the lowest price it dropped to was $48.06. The 52-week range on TARS shows that it touched its highest point at $52.99 and its lowest point at $15.60 during that stretch. It currently has a 1-year price target of $65.00. Beta for the stock currently stands at 1.01.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of TARS was up-trending over the past week, with a rise of 5.91%, but this was up by 25.18% over a month. Three-month performance surged to 86.83% while six-month performance rose 43.11%. The stock gained 194.54% in the past year, while it has gained 145.23% so far this year. A look at the trailing 12-month EPS for TARS yields -3.81 with Next year EPS estimates of -1.81. For the next quarter, that number is -0.77. This implies an EPS growth rate of 29.65% for this year and 44.23% for next year.
Float and Shares Shorts:
At present, 34.21 million TARS shares are outstanding with a float of 32.56 million shares on hand for trading. On 2024-11-15, short shares totaled 7.14 million, which was 1868.0 higher than short shares on 1728950400. In addition to Dr. Bobak R. Azamian M.D. as the firm’s Co-Founder, President, CEO & Chairman, Mr. Jeffrey S. Farrow CPA serves as its CFO & Chief Strategy Officer.
Institutional Ownership:
Through their ownership of 1.21338 of TARS’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, TARS reported revenue of $48118000.0 and operating income of -$25162000.0. The EBITDA in the recently reported quarter was -$20820000.0 and diluted EPS was -$0.61.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for TARS since 4 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With TARS analysts setting a high price target of 84.0 and a low target of 41.0, the average target price over the next 12 months is 65.33333. Based on these targets, TARS could surge 69.15% to reach the target high and fall by -17.44% to reach the target low. Reaching the average price target will result in a growth of 31.56% from current levels.
Analysts have provided yearly estimates in a range of -$3.01713 being high and -$3.46262 being low. For TARS, this leads to a yearly average estimate of -$3.25.
